ERBB2 and breast carcinoma: Multiple mechanisms have been explored, for example, it has been shown that the radiosensitization by lapatinib is primarily mediated through inhibition of RAF/MEK/ERK pathway and combinatorial approach that also includes inhibitors of this pathway could provide superior strategy for radiosensitization in HER2-positive breast cancers (132).